A major histocompatibility complex (MHC) class I-restricted cytotoxic T-lymphocyte (CTL) response is induced in BALB/c mice upon immunization with poliovirus serotype 1 (Mahoney strain). A similar class I-restricted response is also induced upon immunization with purified VP1 capsid proteins. Thus, poliovirus-specific MHC class I CTL responses can be induced independently of viral infection in murine hosts. In experiments using recombinant vaccinia virus vectors expressing different segments of the poliovirus capsid proteins and synthetic peptides, two regions of the VP1 capsid protein appear to contain epitopes recognized by this bulk CTL population. These epitope regions contain a Kd-restricted peptide-binding motif. Interestingly, each of these CTL epitopes is located near previously defined neutralizing antigenic sites.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC241474 | PMC |
| http://dx.doi.org/10.1128/JVI.66.10.5967-5974.1992 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ribosome profiling shows variable sensitivity to detect open reading frames for conventional and different types of cryptic T cell antigens.
Mol Ther Methods Clin Dev
March 2025
Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands.
T cell-based immunotherapies targeting antigens on tumor cells have shown efficacy as anti-cancer treatments. While neoantigens are created by somatic mutations acquired during tumorigenesis, allogeneic stem cell transplantation as treatment for hematological malignancies exploits minor histocompatibility antigens encoded by genetic differences between patients and donors. Screening methods to predict neoantigens and minor histocompatibility antigens typically consider only conventional antigens created by nonsynonymous mutations or polymorphisms coding for amino acid changes in canonical open reading frames (ORFs).
View Article and Find Full Text PDFHigh-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen PRAME.
Immunother Adv
November 2024
Immunocore Limited, Abingdon, Oxfordshire, United Kingdom.
Background: PRAME (eferentially expressed ntigen in lanoma) is a cancer-testis antigen expressed in several tumor indications, representing an attractive anticancer target. However, its intracellular location limits targeting by traditional methods. PRAME peptides are presented on the surface of tumor cells by human leukocyte antigen (HLA) molecules, indicating that a T cell receptor (TCR)-based strategy that redirects T cells to kill PRAME tumors could be a novel immunotherapeutic option.
View Article and Find Full Text PDFLongitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients.
Cell Host Microbe
November 2024
Department of Experimental Oncology, Istituto Europeo di Oncologia-IRCCS, Milan 20139, Italy. Electronic address:
Immune checkpoint inhibitors (ICIs) improve outcomes in advanced melanoma, but many patients are refractory or experience relapse. The gut microbiota modulates antitumor responses. However, inconsistent baseline predictors point to heterogeneity in responses and inadequacy of cross-sectional data.
View Article and Find Full Text PDFAML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.
Front Oncol
October 2024
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.
Article Synopsis
- Acute myeloid leukemia (AML) has a poor prognosis mainly due to the relapse driven by therapy-resistant leukemia progenitor/stem cells (LPCs), leading to the development of peptide-based immunotherapy targeting these cells to improve patient outcomes.
- A therapeutic vaccine called AML-VAC-XS15 was created, consisting of specific peptides from common AML mutations, and is being tested in a phase I clinical trial for its effectiveness and safety in AML patients in remission.
- The study is ethically approved and aims to evaluate the vaccine's ability to generate immune responses and assess its preliminary clinical efficacy while ensuring patient safety through monitoring over two years.
Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Nat Commun
October 2024
Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Australia.
Article Synopsis
- Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are severe skin reactions to drugs, involving immune system responses from CD8 T cells.
- Researchers analyzed skin and blister fluid from 15 SJS/TEN patients using various sequencing techniques, revealing 15 distinct cell types and noting active immune responses in affected areas.
- Key findings indicate that certain T cell receptors and inflammatory markers in skin tissues could be targeted for new treatments, highlighting the role of keratinocytes and T cells in the disease's progression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!